SOPH

SOPH

Sophia Genetics SA

Revenue grew 100% of years5Y
Hold

Sophia Genetics SA develops the SOPHiA DDM platform, a cloud-based software for analyzing multimodal healthcare data. Its solutions support hospitals, laboratories, and biopharmaceutical firms in clinical genomics across multiple global markets.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago $417today

Score Overview

1 Year
Score
Net Growth-2.38%
Net TrendShrank
Net Income Consistency
Rev Growth11.51%
Rev TrendGrew
Revenue Consistency
5 Years
Score5.2
Net Growth-9.78%
Net Trend40%
Net Income Consistency
Rev Growth113.02%
Rev TrendEvery year
Revenue Consistency
All Time
Score
Net Growth-9.78%
Net Trend40%
Net Income Consistency
Rev Growth113.02%
Rev TrendEvery year
Revenue Consistency

See the full market ranking →

Sophia Genetics SA fundamental performance

Between 2021 and 2025, revenue grew from $ 40M to $ 77M and net income went from -$ 73M to -$ 78M. Revenue increased in 100% of the years measured; net income in 40%.

Sophia Genetics SA currently holds a 5-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.57
1 Year2025-08-12
$ 3.14141.08%
5 Years2021-08-12
$ 18.14-58.27%
All Time2021-07-23
$ 16.76-54.83%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 86M-$ 80M
2025$ 77M-$ 78M$ 70M
2024$ 65M-$ 62M$ 80M
2023$ 62M-$ 78M$ 123M
2022$ 47M-$ 87M$ 178M
IPO2021$ 40M-$ 73M$ 265M

Explore beyond SOPH

You're looking at Sophia Genetics SA. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies